Caris Life Sciences (CAI) Cash from Financing Activities (2024 - 2026)

Caris Life Sciences' Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $824000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 35.88% year-over-year to $824000.0; the TTM figure through Mar 2026 stood at $664.5 million (changed N/A YoY), while the FY2025 annual figure was $665.0 million, up 232.01% from the prior year.
• Cash from Financing Activities was $824000.0 for Q1 2026 at Caris Life Sciences, down from $3.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $681.4 million in Q2 2025 to a low of -$21.1 million in Q3 2025.
• Historically, Cash from Financing Activities has averaged $95.2 million across 3 years, with a median of $824000.0 in 2026.
• Biggest YoY gain for Cash from Financing Activities was 1403.98% in 2025; the steepest drop was 24349.43% in 2025.
• A 3-year view of Cash from Financing Activities shows it stood at $226000.0 in 2024, then surged by 1403.98% to $3.4 million in 2025, then plunged by 75.76% to $824000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $824000.0 (Q1 2026), $3.4 million (Q4 2025), and -$21.1 million (Q3 2025), per Business Quant data.